The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. This project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of Qilu Hospital of Shandong University will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. After 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.
Study Type
OBSERVATIONAL
Enrollment
210
Vericiguat in addition to conventional treatment
Conventional treatment only
Qilu Hospital of Shandong University
Jinan, Shandong, China
Central Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China
The First Affiliated Hospital of Shandong First Medical University/Shandong Province Qianfoshan Hospital
Jinan, Shandong, China
LVEDVI=LVEDV/BSA
Changes of left ventricular end-diastolic volume index (LVEDVI) compared with baseline after 12 months
Time frame: From baseline to the end of 12-month treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.